CY1125361T1 - Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση - Google Patents

Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση

Info

Publication number
CY1125361T1
CY1125361T1 CY20211100863T CY211100863T CY1125361T1 CY 1125361 T1 CY1125361 T1 CY 1125361T1 CY 20211100863 T CY20211100863 T CY 20211100863T CY 211100863 T CY211100863 T CY 211100863T CY 1125361 T1 CY1125361 T1 CY 1125361T1
Authority
CY
Cyprus
Prior art keywords
carbohydrates
pharmaceutical preparation
therapeutic use
carbohydrate
cdg type
Prior art date
Application number
CY20211100863T
Other languages
English (en)
Inventor
Agnes RAFALKO
Tatyana CHERNENKO
Original Assignee
Glycomine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomine, Inc. filed Critical Glycomine, Inc.
Publication of CY1125361T1 publication Critical patent/CY1125361T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Η φανέρωση παρέχει μεθόδους για παρασκευή θεραπειών υποκατάστασης υδατανθράκων (CRT) που περιλαμβάνουν νανοφορείς υδατανθράκων και γλυκολιπίδια για φαρμακευτική διανομή στο εσωτερικό των κυττάρων, ενδοπλασματικό δίκτυο, και Golgi για αντιμετώπιση νόσων CDG τύπου Ι και CDG τύπου II όπως επίσης και άλλων μεταβολικών διαταραχών.
CY20211100863T 2013-09-16 2021-10-05 Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση CY1125361T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361878591P 2013-09-16 2013-09-16
PCT/US2014/055921 WO2015053910A2 (en) 2013-09-16 2014-09-16 Pharmaceutical preparation of carbohydrates for therapeutic use

Publications (1)

Publication Number Publication Date
CY1125361T1 true CY1125361T1 (el) 2023-03-24

Family

ID=52813726

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100863T CY1125361T1 (el) 2013-09-16 2021-10-05 Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση

Country Status (13)

Country Link
US (5) US20160228364A1 (el)
EP (2) EP3046537B1 (el)
CY (1) CY1125361T1 (el)
DK (1) DK3046537T3 (el)
ES (1) ES2892314T3 (el)
HR (1) HRP20211564T1 (el)
HU (1) HUE056624T2 (el)
LT (1) LT3046537T (el)
PL (1) PL3046537T3 (el)
PT (1) PT3046537T (el)
RS (1) RS62641B1 (el)
SI (1) SI3046537T1 (el)
WO (1) WO2015053910A2 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205530A1 (en) * 2019-03-29 2020-10-08 Glycomine, Inc. Liposomal formulations, and methods of using and preparing thereof
US11058637B1 (en) * 2020-11-25 2021-07-13 King Abdulaziz University Surface-modified emulsomes for intranasal delivery of drugs
WO2023225102A1 (en) * 2022-05-18 2023-11-23 Glycomine, Inc. Continuous flow methods for producing mannose-1-phosphate, polymorphs of mannose-1-phosphate, and compositions and uses related thereto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US7189705B2 (en) * 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
US7914714B2 (en) * 2003-05-14 2011-03-29 The Regents Of The University Of Colorado Methods and apparatus using electrostatic atomization to form liquid vesicles
FR2897779B1 (fr) * 2006-02-24 2009-04-17 Orphan Europ Sarl Manossyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis dy syndrome cdg-la
EP2282723A2 (en) 2008-03-26 2011-02-16 University of Oxford Endoplasmic reticulum targeting liposomes
US20120135064A1 (en) * 2009-05-27 2012-05-31 Northeastern University Conjugated nanodelivery vehicles
KR101762466B1 (ko) 2009-12-23 2017-07-27 노파르티스 아게 지질, 지질 조성물 및 이의 사용 방법
US20110257233A1 (en) 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
EP2598120B1 (en) * 2010-07-31 2018-09-05 The Scripps Research Institute Compositions and methods for inducing immune tolerance

Also Published As

Publication number Publication date
US10449149B2 (en) 2019-10-22
EP3046537B1 (en) 2021-07-14
US20200246266A1 (en) 2020-08-06
EP3046537A2 (en) 2016-07-27
US20220110871A1 (en) 2022-04-14
US20160228364A1 (en) 2016-08-11
PL3046537T3 (pl) 2022-01-31
HUE056624T2 (hu) 2022-02-28
DK3046537T3 (da) 2021-10-11
PT3046537T (pt) 2021-10-07
ES2892314T3 (es) 2022-02-03
EP3954360A2 (en) 2022-02-16
EP3954360A3 (en) 2022-06-01
US11045419B2 (en) 2021-06-29
LT3046537T (lt) 2021-12-10
RS62641B1 (sr) 2021-12-31
US20180036239A1 (en) 2018-02-08
US20240082155A1 (en) 2024-03-14
WO2015053910A2 (en) 2015-04-16
EP3046537A4 (en) 2017-04-19
HRP20211564T1 (hr) 2022-01-21
SI3046537T1 (sl) 2022-01-31
WO2015053910A3 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
CY1125361T1 (el) Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση
CY1121348T1 (el) Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων
CA2895175C (en) Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
BR112016009077A2 (pt) Formulações lipídicas para fornecimento de rna mensageiro
MY188139A (en) Sodium channel modulators for the treatment of pain
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
TN2016000007A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
EP4360621A3 (en) Formulations of bendamustine
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
EA201391689A1 (ru) Система доставки лекарственного средства
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
MX362485B (es) Nuevos inhibidores de rock.
MX2021011876A (es) Formulaciones liposomicas y metodos de uso y preparacion de las mismas.
WO2014184726A3 (en) Compounds and their use in therapy
PH12016501347A1 (en) Filters for infusion sets
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
NZ740722A (en) Oral suspension for treating eosinophilic esophagitis
EA201992463A1 (ru) Система доставки лекарственного средства
UA63647U (ru) Способ лечения алкогольной зависимости
UA113061C2 (xx) Система доставки лікарського засобу